Insights

Washington – June 4, 2026: Crowell & Moring earned 92 individual rankings for 81 attorneys, as well as 48 national and statewide practice area rankings, in the Chambers USA 2026 guide. The Chambers guide ranks the country’s top law firms and lawyers through in-depth research, client interviews, and feedback from attorneys at peer firms. 

Boston – October 15, 2025: Jeffrey S. Gleason, an accomplished first-chair trial attorney and former leader in the Civil Fraud Section of the U.S. Department of Justice, has joined Crowell & Moring as a partner, further bolstering the firm’s fast-growing and industry-leading Health Care Group.

Washington – June 26, 2025: Crowell & Moring has been recommended in eight practice areas in the 18th edition of the Legal 500 United States. In addition, partner Daniel Forman, co-chair of the firm’s Government Contracts Group, has been named to the Legal 500’s “Hall of Fame” for Government Contracts.

With the Centers for Medicare & Medicaid Services (CMS) poised to determine which organ procurement organizations (OPO) will retain their Medicare certification and service territories under a controversial new performance framework, a coalition of OPOs is fighting to have its day in court — but first, it must convince a federal judge that the courthouse doors are open to it at all. The U.S. District Court for the Middle District of Florida is actively weighing whether it has jurisdiction to hear a pre-enforcement challenge to a 2020 Final Rule, which introduced a competitive three-tier performance model that threatens lower-performing OPOs with the loss of their designated service areas (DSA) and, potentially, their Medicare certifications. The resolution of this threshold question will determine whether the plaintiff OPOs can seek judicial relief ahead of decertification proceedings, which CMS has signaled will occur after it finalizes its 2026 Proposed Rule at the end of the year.

In keeping with ongoing efforts to intensify regulatory oversight of organ procurement organizations (OPOs) and curtail improper spending within federal health programs, the Centers for Medicare & Medicaid Services (CMS) recently issued a proposed rule that would, among other adjustments, align Medicare payment policies for non-renal organs to be consistent with those currently applicable to kidneys. If enacted as drafted, this latest rule could have a direct impact on the financial stability of OPOs and histocompatibility laboratories (HCL) at a time when such organizations face increasing pressure to meet CMS’s new outcome measures — or else face non-renewal or decertification later this year. 

2026 will prove to be a pivotal year for organ procurement organizations (OPOs). For the first time, the impact of the Center for Medicare and Medicaid Services’ (CMS) 2020 outcome measures will be fully felt, as the year marks the end of the first certification cycle governed by the new benchmarks. In the meantime, OPOs are challenging the 2020 rule in several federal lawsuits and, as that litigation progresses, CMS is accepting comments on a new proposed rule, which we discussed in a prior alert. 

Changes in the health care delivery and payment system are underway to “bend the cost curve” and improve patient outcomes. However, the legal and compliance risks to any entity offering services or products paid for or reimbursed with government dollars have not abated.

Please join us for the 2018 Inova Discovery Series: Early Stage Investing in Health Technology Event on Thursday, June 21, 2018.

Our health care landscape is rapidly transforming. As the health care space has become more digitized and more reliant on technology than ever before, artificial intelligence (AI), telehealth services, data analysis, and medical devices have become drivers of our health care system. Likewise, value-based care is becoming increasingly popular among delivery systems, leaving accountable care organizations (ACOs) to adhere to changing federal compliance requirements. The burden falls on health care entities to remain up-to-date on how care is evolving as federal and state compliance regulations and privacy concerns continue to develop.

In this episode, Troy Barsky interviews Michael Meng (the CEO of Stellar Health) about how technology has impacted, and continues to impact, health care delivery in light of regulatory changes focused on advancing value-based care.  Michael Meng is the CEO and co-founder of Stellar Health, which is a healthcare technology company focused on enabling success across the value-based care continuum by bridging the incentive gap between providers and payors.

In this episode, hosts Payal Nanavati and Joe Records talk to Troy Barsky and Roma Sharma about their reflections on the first year of implementation of new regulations implementing the major fraud and abuse statutes — the Stark Law and Anti-Kickback Statute (AKS) — including discussing challenges, opportunities, and outstanding questions about the new exceptions and safe harbors for value-based care.

Payers, Providers, and Patients – Oh My! Is Crowell & Moring’s biweekly health care podcast, discussing legal and regulatory issues that affect health care entities’ in-house counsel, executives, and investors. In this episode, hosts Payal Nanavati and Joe Records talk with Troy Barsky and Alice Hall-Partyka about how recent litigation challenging the constitutionality of the Affordable Care Act may impact providers and payers. The discussion focuses on the authority for innovative health care models and important fraud and abuse provisions that were enacted in the ACA.